Page Nct des essais cliniques

Summary
EudraCT Number:2022-000811-29
Sponsor's Protocol Code Number:I6T-MC-AMAY
National Competent Authority:Italy - Italian Medicines Agency
Clinical Trial Type:EEA CTA
Trial Status:Ongoing
Date on which this record was first entered in the EudraCT database:2022-12-21
Trial results
Index
A. PROTOCOL INFORMATION
B. SPONSOR INFORMATION
C. APPLICANT IDENTIFICATION
D. IMP IDENTIFICATION
D.8 INFORMATION ON PLACEBO
E. GENERAL INFORMATION ON THE TRIAL
F. POPULATION OF TRIAL SUBJECTS
G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
P. END OF TRIAL
A. Protocol Information
A.1Member State ConcernedItaly - Italian Medicines Agency
A.2EudraCT number2022-000811-29
A.3Full title of the trial
A Phase 3, Multicenter, Randomized, Platform Study of p19 Inhibition of the IL-23 Pathway to Establish Efficacy in Pediatric Crohn’s Disease
Studio piattaforma di fase 3, multicentrico, randomizzato sull’inibizione di p19 della via di segnalazione dell’IL-23 per stabilire l’efficacia in pazienti pediatrici con malattia di Crohn
A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
A Phase 3, Multicenter, Randomized in Pediatric Crohn’s Disease
Studio clinico di fase 3, multicentrico, randomizzato per valutare mirikizumab in pazienti pediatrici con malattia di Crohn
A.3.2Name or abbreviated title of the trial where available
MACARONI-23
MACARONI-23
A.4.1Sponsor's protocol code numberI6T-MC-AMAY
A.5.2US NCT (ClinicalTrials.gov registry) numberNCT05509777
A.5.4Other Identifiers
Name:Sponsor's Master Protocol code numberNumber:PLATFORMPBCRD3001/16T-MC-PIBD
A.7Trial is part of a Paediatric Investigation Plan Yes
A.8EMA Decision number of Paediatric Investigation PlanP/065/2022
B. Sponsor Information
B.Sponsor: 1
B.1.1Name of SponsorELI LILLY & COMPANY, LILLY CORPORATE CENTER
B.1.3.4CountryUnited States
B.3.1 and B.3.2Status of the sponsorCommercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1Name of organisation providing supportEli Lilly and Company
B.4.2CountryUnited States
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1Name of organisationEli Lilly and Company
B.5.2Functional name of contact pointClinical Trial Registry Office
B.5.3 Address:
B.5.3.1Street AddressLilly Corporate Center, DC 1526
B.5.3.2Town/ cityIndianapolis,
B.5.3.3Post codeIN 46285
B.5.3.4CountryUnited States
B.5.4Telephone number00000000
B.5.5Fax number00000000
B.5.6E-mailEU_Lilly_clinical_Trials@Lilly.com
D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3IMP RoleTest
D.2 Status of the IMP to be used in the clinical trial
D.2.1IMP to be used in the trial has a marketing authorisation No
D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
D.2.5.1Orphan drug designation number
D.3 Description of the IMP
D.3.1Product namemirikizumab
D.3.2Product code [LY3074828]
D.3.4Pharmaceutical form Solution for injection/infusion
D.3.4.1Specific paediatric formulation No
D.3.7Routes of administration for this IMPSubcutaneous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8INN - Proposed INNMirikizumab
D.3.9.2Current sponsor codeLY3074828
D.3.9.4EV Substance CodeSUB217204
D.3.10 Strength
D.3.10.1Concentration unit mg/l milligram(s)/litre
D.3.10.2Concentration typeequal
D.3.10.3Concentration number100
D.3.11 The IMP contains an:
D.3.11.1Active substance of chemical origin No
D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
The IMP is a:
D.3.11.3Advanced Therapy IMP (ATIMP) No
D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
D.3.11.3.2Gene therapy medical product Information not present in EudraCT
D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
D.3.11.5Radiopharmaceutical medicinal product No
D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
D.3.11.7Plasma derived medicinal product No
D.3.11.8Extractive medicinal product No
D.3.11.9Recombinant medicinal product Yes
D.3.11.10Medicinal product containing genetically modified organisms No
D.3.11.11Herbal medicinal product No
D.3.11.12Homeopathic medicinal product No
D.3.11.13Another type of medicinal product No
D.IMP: 2
D.1.2 and D.1.3IMP RoleTest
D.2 Status of the IMP to be used in the clinical trial
D.2.1IMP to be used in the trial has a marketing authorisation No
D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
D.2.5.1Orphan drug designation number
D.3 Description of the IMP
D.3.1Product namemirikizumab
D.3.2Product code [LY3074828]
D.3.4Pharmaceutical form Solution for infusion
D.3.4.1Specific paediatric formulation No
D.3.7Routes of administration for this IMPIntravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8INN - Proposed INNMirikizumab
D.3.9.2Current sponsor codeLY3074828
D.3.9.4EV Substance CodeSUB217204
D.3.10 Strength
D.3.10.1Concentration unit mg/g milligram(s)/gram
D.3.10.2Concentration typeequal
D.3.10.3Concentration number20
D.3.11 The IMP contains an:
D.3.11.1Active substance of chemical origin No
D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
The IMP is a:
D.3.11.3Advanced Therapy IMP (ATIMP) No
D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
D.3.11.3.2Gene therapy medical product Information not present in EudraCT
D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
D.3.11.5Radiopharmaceutical medicinal product No
D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
D.3.11.7Plasma derived medicinal product No
D.3.11.8Extractive medicinal product No
D.3.11.9Recombinant medicinal product Yes
D.3.11.10Medicinal product containing genetically modified organisms No
D.3.11.11Herbal medicinal product No
D.3.11.12Homeopathic medicinal product No
D.3.11.13Another type of medicinal product No
D.IMP: 3
D.1.2 and D.1.3IMP RoleTest
D.2 Status of the IMP to be used in the clinical trial
D.2.1IMP to be used in the trial has a marketing authorisation No
D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
D.2.5.1Orphan drug designation number
D.3 Description of the IMP
D.3.1Product namemirikizumab
D.3.2Product code [LY3074828]
D.3.4Pharmaceutical form Solution for injection/infusion
D.3.4.1Specific paediatric formulation No
D.3.7Routes of administration for this IMPSubcutaneous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8INN - Proposed INNMirikizumab
D.3.9.2Current sponsor codeLY3074828
D.3.9.4EV Substance CodeSUB217204
D.3.10 Strength
D.3.10.1Concentration unit mg/l milligram(s)/litre
D.3.10.2Concentration typeequal
D.3.10.3Concentration number100
D.3.11 The IMP contains an:
D.3.11.1Active substance of chemical origin No
D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
The IMP is a:
D.3.11.3Advanced Therapy IMP (ATIMP) No
D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
D.3.11.3.2Gene therapy medical product Information not present in EudraCT
D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
D.3.11.5Radiopharmaceutical medicinal product No
D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
D.3.11.7Plasma derived medicinal product No
D.3.11.8Extractive medicinal product No
D.3.11.9Recombinant medicinal product Yes
D.3.11.10Medicinal product containing genetically modified organisms No
D.3.11.11Herbal medicinal product No
D.3.11.12Homeopathic medicinal product No
D.3.11.13Another type of medicinal product No
D.8 Information on Placebo
E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1Medical condition(s) being investigated
Clinical Study to Evaluate Mirikizumab in Pediatric Crohn’s Disease
Studio clinico per valutare Mirikizumab nella malattia di Crohn pediatrica
E.1.1.1Medical condition in easily understood language
Crohn’s Disease
Malattia di Crohn
E.1.1.2Therapeutic area Diseases [C] - Digestive System Diseases [C06]
MedDRA Classification
E.1.2 Medical condition or disease under investigation
E.1.2Version 20.0
E.1.2Level SOC
E.1.2Classification code 10017947
E.1.2Term Gastrointestinal disorders
E.1.2System Organ Class 10017947 - Gastrointestinal disorders
E.1.3Condition being studied is a rare disease No
E.2 Objective of the trial
E.2.1Main objective of the trial
To evaluate whether treatment with IL-23 inhibitors is superior to adult placebo in achieving clinical remission and endoscopic response in pediatric participants with moderately to severely active CD at Week 52 who do not require modification of IP regimen, IP rescue therapy, or non-IP rescue therapy
Valutare se il trattamento con gli inibitori dell’IL-23 sia superiore al placebo degli adulti nell’ottenere una remissione clinica e una risposta endoscopica nei partecipanti pediatrici con MC in fase attiva da moderata a grave alla Settimana 52 che non richiedono una modifica del regime IP, terapia di soccorso con IP o terapia di soccorso senza IP
E.2.2Secondary objectives of the trial
To evaluate the efficacy of treatment with mirikizumab in achieving clinical response or clinical remission by PCDAI or CDAI at Week 12
Valutare l’efficacia del trattamento con mirikizumab nel raggiungimento della risposta clinica o della remissione clinica secondo il PCDAI o il CDAI alla Settimana 12
E.2.3Trial contains a sub-study No
E.3Principal inclusion criteria
1.Participants must have a diagnosis of CD or fistulizing CD, with active colitis, ileitis, or ileocolitis, confirmed at any time in the past by clinical, endoscopic, and histologic criteria.
2.Participants must have moderately to severely active CD (as defined by a baseline PCDAI score >30).
3.Participants must have endoscopy with evidence of active CD defined as as SES-CD score =6 (or =4 for participants with isolated ileal disease) during screening into this study.
4.Participants must have a prior or current CD medication history that includes either inadequate response, loss of response to or failure to tolerate current treatment immunomodulators or with oral or IV corticosteroids or have received biologic therapy/JAK inhibitor for the treatment of CD and have a documented history of inadequate response, loss of response (LOR), or intolerance to the biologic therapy/JAK inhibitor.
1. I partecipanti devono presentare una diagnosi di MC o MC fistolizzante, con colite, ileite o ileocolite attiva, confermata in qualsiasi momento in passato dai criteri clinici, endoscopici e istologici.
2. I partecipanti devono presentare MC in fase attiva da moderata a grave (come definito da un punteggio PCDAI al basale >30).
3. I partecipanti devono presentare endoscopia con evidenza di MC attiva definita come punteggio SES CD =6 (o =4 per i partecipanti con malattia ileale isolata) durante lo screening in questo studio.
4. I partecipanti devono presentare un’anamnesi pregressa o attuale di farmaci per la MC che includa una risposta inadeguata, una perdita della risposta o una mancata tolleranza dell’attuale trattamento con immunomodulatori o con corticosteroidi per via orale o EV oppure avere ricevuto una terapia biologica/inibitore di JAK per il trattamento della MC e presentare un’anamnesi documentata di risposta inadeguata, perdita della risposta (LOR) o intolleranza alla terapia biologica/inibitore di JAK.
E.4Principal exclusion criteria
1. Participants must not have complications of CD such as symptomatic strictures or stenosis, short gut syndrome, or any other manifestations that might be anticipated to require surgery.
2. Participants must not have an abscess.
3. Participants must not have any kind of bowel resection within 26 weeks or any other intra-abdominal surgery within 12 weeks of baseline.
1. I partecipanti non devono presentare complicanze di MC come aderenze o stenosi sintomatiche, sindrome dell’intestino corto o qualsiasi altra manifestazione che si prevede possa richiedere un intervento chirurgico.
2. I partecipanti non devono avere un ascesso.
3. I partecipanti non devono essere sottoposti ad alcun tipo di resezione intestinale nelle 26 settimane o qualsiasi altro intervento chirurgico intra-addominale nelle 12 settimane precedenti il basale.
E.5 End points
E.5.1Primary end point(s)
1.Percentage of Participants with Clinical Response by Pediatric Crohn's Disease Activity Index (PCDAI) at Week 12 and Endoscopic Response by Simple Endoscopic Score for CD (SES-CD) at Week 52 [ Time Frame: Baseline to Week 52 ]
Clinical response based on PCDAI, and endoscopic response based on SES-CD

2.Percentage of Participants with a Clinical Response by PCDAI at Week 12 and Clinical Remission by PCDAI at Week 52 [ Time Frame: Baseline to Week 52 ]
Clinical response based on PCDAI, and clinical remission based on PCDAI
1. Percentuale di partecipanti con risposta clinica in base all’Indice di attività della malattia di Crohn in età pediatrica (PCDAI) alla Settimana 12 e risposta endoscopica tramite punteggio endoscopico semplice per la MC (SES-CD) alla Settimana 52 [Intervallo di tempo: dal basale alla Settimana 52]
Risposta clinica basata sul PCDAI e risposta endoscopica basata sul SES-CD

2. Percentuale di partecipanti con risposta clinica secondo il PCDAI alla Settimana 12 e remissione clinica secondo il PCDAI alla Settimana 52 [Intervallo di tempo: dal basale alla Settimana 52]
Risposta clinica in base al PCDAI e remissione clinica in base al PCDAI
E.5.1.1Timepoint(s) of evaluation of this end point
Week 52
Settimana 52
E.5.2Secondary end point(s)
1.Percentage of Participants Achieving Clinical Response by PCDAI [ Time Frame: Week 12 ]
Clinical response based on PCDAI

2.Percentage of Participants Achieving Clinical Response by Clinical Disease Activity Index (CDAI) [ Time Frame: Week 12 ]
Clinical response based on CDAI for participants =12 years of age

3.Percentage of Participants Achieving Clinical Remission by PCDAI [ Time Frame: Week 12 ]
Clinical remission based on PCDAI

4.Percentage of Participants Achieving Clinical Remission by CDAI [ Time Frame: Week 12 ]
Clinical remission based on CDAI for participants =12 years of age

5.Percentage of Participants Achieving Endoscopic Response by SES-CD [ Time Frame: Week 12 ]
Endoscopic response based on SES-CD

6.Percentage of Participants Achieving Clinical Response by PCDAI at Week 12 and Endoscopic Remission by SES-CD at Week 52 [ Time Frame: Baseline to Week 52 ]
7.Change from Baseline in C-reactive Protein (CRP) [ Time Frame: Baseline, Week 12 ]
8.Change from Baseline in CRP [ Time Frame: Baseline, Week 52 ]
9.Change from Baseline in Fecal calprotectin [ Time Frame: Baseline, Week 12 ]
10.Change from Baseline in Fecal calprotectin [ Time Frame: Baseline, Week 52 ]
11.Percentage of Participants Achieving Clinical Response PCDAI at Week 12 and Clinical Remission by CDAI at Week 52 [ Time Frame: Baseline to Week 52 ]
Clinical response by PCDAI, CDAI for participants =12 years of age

12.Percentage of Participants Achieving Endoscopic Response [ Time Frame: Week 52 ]
Endoscopic response by SES-CD

13.Percentage of Participants Achieving Clinical Remission by PCDAI [ Time Frame: Week 52 ]
Clinical remission based on PCDAI

14.Percentage of Participants Achieving Clinical Response by PCDAI at Week 12 and PCDAI Clinical Remission without the use of Corticosteroids and who did not have Crohn's disease (CD)-Related Surgery at Week 52 [ Time Frame: Baseline to Week 52 ]
Clinical response and clinical remission by PCDAI

15.Pharmacokinetics (PK): Clearance of Mirikizumab [ Time Frame: Baseline through Week 52 ]
16.Pharmacokinetics (PK): Volume of Distribution of Mirikizumab [ Time Frame: Baseline through Week 52 ]
; 1. Percentuale di partecipanti che ottengono una risposta clinica secondo PCDAI [Intervallo di tempo: Settimana 12]
Risposta clinica in base al PCDAI
2. Percentuale di partecipanti che ottengono una risposta clinica in base all’Indice di attività della malattia clinica (CDAI) [Intervallo di tempo: Settimana 12]
Risposta clinica basata sul CDAI per i partecipanti di età =12 anni
3. Percentuale di partecipanti che ottengono la remissione clinica in base al PCDAI [Intervallo di tempo: Settimana 12]
Remissione clinica in base al PCDAI
4. Percentuale di partecipanti che ottengono la remissione clinica in base al CDAI [Intervallo di tempo: Settimana 12]
Remissione clinica basata sul CDAI per partecipanti di età =12 anni
5. Percentuale di partecipanti che ottengono una risposta endoscopica in base al SES-CD [Intervallo di tempo: Settimana 12]
Risposta endoscopica in base SES-CD
6. Percentuale di partecipanti che ottengono la risposta clinica in base al PCDAI alla Settimana 12 e la remissione endoscopica in base al SES-CD alla Settimana 52 [Intervallo di tempo: dal basale alla Settimana 52]
7. Variazione dal basale nella proteina C-reattiva (CRP) [Intervallo di tempo: Basale, Settimana 12]
8. Variazione dal basale nella CRP [Intervallo di tempo: Basale, Settimana 52]
9. Variazione dal basale nella calprotectina fecale [Intervallo di tempo: Basale, Settimana 12]
10. Variazione dal basale nella calprotectina fecale [Intervallo di tempo: Basale, Settimana 52]
11. Percentuale di partecipanti che ottengono una risposta clinica in base al PCDAI alla Settimana 12 e remissione clinica in base al CDAI alla Settimana 52 [Intervallo di tempo: dal basale alla Settimana 52]
Risposta clinica in base al PCDAI, CDAI per i partecipanti di età =12 anni
12. Percentuale di partecipanti che ottengono la risposta endoscopica [Intervallo di tempo: Settimana 52]
Risposta endoscopica in base al SES-CD
13. Percentuale di partecipanti che ottengono la remissione clinica in base al PCDAI [Intervallo di tempo: Settimana 52]
Remissione clinica in base al PCDAI
14 Percentuale di partecipanti che ottengono la risposta clinica in base al PCDAI alla Settimana 12 e la remissione clinica in base al PCDAI senza l’uso di corticosteroidi e che non sono stati sottoposti a intervento chirurgico connesso alla malattia di Crohn alla Settimana 52 [Intervallo di tempo: dal basale alla Settimana 52]
Risposta clinica e remissione clinica in base al PCDAI
15. Farmacocinetica (PK): Clearance di mirikizumab [Intervallo di tempo: dal basale alla fine della Settimana 52]
16. Farmacocinetica (PK): Volume di distribuzione di mirikizumab [Intervallo di tempo: dal basale alla fine della Settimana 52]
E.5.2.1Timepoint(s) of evaluation of this end point
Week 52
Settimana 52
E.6 and E.7 Scope of the trial
E.6Scope of the trial
E.6.1Diagnosis No
E.6.2Prophylaxis No
E.6.3Therapy No
E.6.4Safety Yes
E.6.5Efficacy Yes
E.6.6Pharmacokinetic No
E.6.7Pharmacodynamic No
E.6.8Bioequivalence No
E.6.9Dose response Yes
E.6.10Pharmacogenetic No
E.6.11Pharmacogenomic No
E.6.12Pharmacoeconomic No
E.6.13Others No
E.7Trial type and phase
E.7.1Human pharmacology (Phase I) No
E.7.1.1First administration to humans No
E.7.1.2Bioequivalence study No
E.7.1.3Other No
E.7.1.3.1Other trial type description
E.7.2Therapeutic exploratory (Phase II) No
E.7.3Therapeutic confirmatory (Phase III) Yes
E.7.4Therapeutic use (Phase IV) No
E.8 Design of the trial
E.8.1Controlled Yes
E.8.1.1Randomised Yes
E.8.1.2Open Yes
E.8.1.3Single blind No
E.8.1.4Double blind No
E.8.1.5Parallel group No
E.8.1.6Cross over No
E.8.1.7Other No
E.8.2 Comparator of controlled trial
E.8.2.1Other medicinal product(s) No
E.8.2.2Placebo No
E.8.2.3Other Yes
E.8.2.3.1Comparator description
guselkumab
guselkumab
E.8.2.4Number of treatment arms in the trial2
E.8.3 The trial involves single site in the Member State concerned No
E.8.4 The trial involves multiple sites in the Member State concerned Yes
E.8.4.1Number of sites anticipated in Member State concerned4
E.8.5The trial involves multiple Member States Yes
E.8.5.1Number of sites anticipated in the EEA35
E.8.6 Trial involving sites outside the EEA
E.8.6.1Trial being conducted both within and outside the EEA Yes
E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
Australia
Brazil
Canada
Israel
Japan
Korea, Republic of
United States
Austria
France
Poland
Netherlands
Spain
Switzerland
Czechia
Italy
Belgium
Norway
Portugal
United Kingdom
E.8.7Trial has a data monitoring committee Yes
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
LPLV for this ISA
Ultima visita ultimo paziente per questa ISA
E.8.9 Initial estimate of the duration of the trial
E.8.9.1In the Member State concerned years3
E.8.9.1In the Member State concerned months0
E.8.9.1In the Member State concerned days0
E.8.9.2In all countries concerned by the trial years3
E.8.9.2In all countries concerned by the trial months0
E.8.9.2In all countries concerned by the trial days0
F. Population of Trial Subjects
F.1 Age Range
F.1.1Trial has subjects under 18 Yes
F.1.1.1In Utero No
F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
F.1.1.3Newborns (0-27 days) No
F.1.1.4Infants and toddlers (28 days-23 months) No
F.1.1.5Children (2-11years) Yes
F.1.1.5.1Number of subjects for this age range: 15
F.1.1.6Adolescents (12-17 years) Yes
F.1.1.6.1Number of subjects for this age range: 70
F.1.2Adults (18-64 years) Yes
F.1.2.1Number of subjects for this age range: 5
F.1.3Elderly (>=65 years) No
F.2 Gender
F.2.1Female Yes
F.2.2Male Yes
F.3 Group of trial subjects
F.3.1Healthy volunteers No
F.3.2Patients Yes
F.3.3Specific vulnerable populations No
F.3.3.1Women of childbearing potential not using contraception No
F.3.3.2Women of child-bearing potential using contraception No
F.3.3.3Pregnant women No
F.3.3.4Nursing women No
F.3.3.5Emergency situation No
F.3.3.6Subjects incapable of giving consent personally No
F.3.3.7Others No
F.4 Planned number of subjects to be included
F.4.1In the member state7
F.4.2 For a multinational trial
F.4.2.1In the EEA 40
F.4.2.2In the whole clinical trial 90
F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
As defined in the protocol
Come definito nel protocollo
G. Investigator Networks to be involved in the Trial
N. Review by the Competent Authority or Ethics Committee in the country concerned
N.Competent Authority Decision Authorised
N.Date of Competent Authority Decision2023-03-16
N.Ethics Committee Opinion of the trial applicationFavourable
N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
N.Date of Ethics Committee Opinion2023-02-16
P. End of Trial
P.End of Trial StatusOngoing

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner